# A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

> **NCT05171647** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 208 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab
- **DRUG:** Polatuzumab vedotin
- **DRUG:** Tocilizumab
- **DRUG:** Rituximab
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT05171647
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-25
- **Primary completion:** 2025-02-17
- **Final completion:** 2027-02-28
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05171647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05171647, "A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-09-02 from https://api.ai-analytics.org/clinical/NCT05171647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*